Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dow Inc. stock logo
DOW
DOW
$57.04
+0.4%
$57.45
$47.26
$60.69
$40.11B1.34.17 million shs2.54 million shs
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
$29.43
+1.3%
$32.24
$24.76
$36.19
$747.82M1.25235,774 shs207,908 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$64.78
-0.8%
$70.72
$64.33
$87.86
$80.66B0.227.35 million shs7.82 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dow Inc. stock logo
DOW
DOW
+0.35%-0.45%-4.93%+6.76%+7.60%
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
+1.27%+2.12%-10.55%-1.51%+9.94%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.84%-0.98%-8.62%-15.83%-18.46%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dow Inc. stock logo
DOW
DOW
3.8777 of 5 stars
2.13.02.50.01.91.74.4
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
2.552 of 5 stars
2.31.03.30.02.02.51.9
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9943 of 5 stars
4.25.03.34.13.02.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dow Inc. stock logo
DOW
DOW
2.29
Hold$59.003.44% Upside
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
2.50
Moderate Buy$35.0018.93% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.39
Hold$83.6929.19% Upside

Current Analyst Ratings

Latest GILD, DOW, and ETD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$90.00 ➝ $85.00
4/29/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $76.00
4/26/2024
Dow Inc. stock logo
DOW
DOW
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $62.00
4/26/2024
Dow Inc. stock logo
DOW
DOW
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$55.00 ➝ $61.00
4/26/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $78.00
4/26/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $85.00
4/26/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$76.00 ➝ $74.00
4/26/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/25/2024
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
Telsey Advisory Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$30.00 ➝ $30.00
4/24/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$69.00
4/19/2024
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
Telsey Advisory Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$30.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dow Inc. stock logo
DOW
DOW
$44.62B0.90$6.03 per share9.46$26.90 per share2.12
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
$791.38M0.94$4.74 per share6.21$18.78 per share1.57
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.45B2.94$8.87 per share7.30$14.02 per share4.62

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dow Inc. stock logo
DOW
DOW
$589M$1.6833.9512.790.802.75%8.05%2.71%7/23/2024 (Estimated)
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
$105.81M$2.7510.7012.01N/A10.63%14.93%9.53%8/7/2024 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$5.67B$0.36179.949.001.311.76%24.34%8.36%8/1/2024 (Estimated)

Latest GILD, DOW, and ETD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024Q1 24
Dow Inc. stock logo
DOW
DOW
$0.45$0.56+$0.11$0.39$10.71 billion$10.77 billion    
4/25/2024Q1 2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$1.49-$1.32+$0.17$0.70$6.36 billion$6.69 billion    
4/24/2024Q3 2024
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
$0.66$0.48-$0.18$0.46$168.15 million$146.42 million    
2/6/2024Q4 23
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.76$1.72-$0.04$2.30$7.10 billion$7.12 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dow Inc. stock logo
DOW
DOW
$2.804.91%N/A166.67%N/A
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
$1.444.89%+30.50%52.36%2 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.75%+3.32%855.56%9 Years

Latest GILD, DOW, and ETD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.71%6/14/20246/14/20246/27/2024
4/11/2024
Dow Inc. stock logo
DOW
DOW
quarterly$0.704.9%5/30/20245/31/20246/14/2024
4/22/2024
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
quarterly$0.394.2%5/6/20245/7/20245/23/2024
2/15/2024
Dow Inc. stock logo
DOW
DOW
quarterly$0.705.08%2/28/20242/29/20243/8/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dow Inc. stock logo
DOW
DOW
0.85
1.80
1.18
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
N/A
2.09
1.16
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.08
0.98
0.72

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Dow Inc. stock logo
DOW
DOW
64.00%
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
83.80%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%

Insider Ownership

CompanyInsider Ownership
Dow Inc. stock logo
DOW
DOW
0.50%
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
10.90%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Dow Inc. stock logo
DOW
DOW
35,900703.21 million699.69 millionOptionable
Ethan Allen Interiors Inc. stock logo
ETD
Ethan Allen Interiors
3,74825.41 million22.64 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
18,0001.25 billion1.24 billionOptionable

GILD, DOW, and ETD Headlines

SourceHeadline
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Hold" from BrokeragesGilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Hold" from Brokerages
americanbankingnews.com - May 4 at 3:48 AM
Amalgamated Bank Sells 19,072 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Amalgamated Bank Sells 19,072 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
marketbeat.com - May 3 at 11:38 PM
Forbes Has Listed Gilead as One of America’s Best Employers for DiversityForbes Has Listed Gilead as One of America’s Best Employers for Diversity
finance.yahoo.com - May 3 at 11:36 PM
Gilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42Gilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42
marketbeat.com - May 3 at 8:53 PM
Gilead Sciences (NASDAQ:GILD) PT Lowered to $85.00Gilead Sciences (NASDAQ:GILD) PT Lowered to $85.00
americanbankingnews.com - May 3 at 6:04 AM
McAdam LLC Has $1.63 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)McAdam LLC Has $1.63 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
marketbeat.com - May 3 at 12:08 AM
Gilead gets a boost from California court in a case over slow-walking an HIV drugGilead gets a boost from California court in a case over slow-walking an HIV drug
statnews.com - May 2 at 8:18 PM
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest UpdateGilead Sciences, Inc. (NASDAQ:GILD) Short Interest Update
americanbankingnews.com - May 2 at 3:08 AM
Shhh! 3 Secret Biotech Stocks Flying Below Wall Streets RadarShhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
investorplace.com - May 1 at 2:38 PM
Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $85.00 at Maxim GroupGilead Sciences (NASDAQ:GILD) Price Target Lowered to $85.00 at Maxim Group
marketbeat.com - May 1 at 8:32 AM
Norden Group LLC Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Norden Group LLC Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
marketbeat.com - April 30 at 2:27 PM
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
markets.businessinsider.com - April 30 at 10:53 AM
Gilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology CatalystsGilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology Catalysts
markets.businessinsider.com - April 30 at 10:53 AM
Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $76.00 at BarclaysGilead Sciences (NASDAQ:GILD) Price Target Lowered to $76.00 at Barclays
americanbankingnews.com - April 30 at 6:34 AM
Stock Traders Purchase Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)Stock Traders Purchase Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)
americanbankingnews.com - April 30 at 2:32 AM
Raymond James & Associates Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Raymond James & Associates Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
marketbeat.com - April 29 at 11:30 PM
Gilead Sciences: First-Quarter Results Beat EstimatesGilead Sciences: First-Quarter Results Beat Estimates
fool.com - April 29 at 6:57 PM
Gilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth UncertaintiesGilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth Uncertainties
markets.businessinsider.com - April 29 at 1:48 PM
Traders Purchase Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)Traders Purchase Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)
marketbeat.com - April 29 at 1:01 PM
Barclays Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $76.00Barclays Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $76.00
marketbeat.com - April 29 at 11:36 AM
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com - April 29 at 10:01 AM
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient dataGilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data
clinicaltrialsarena.com - April 29 at 8:48 AM
Gilead Sciences, Inc. to Post FY2024 Earnings of $3.82 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:GILD)Gilead Sciences, Inc. to Post FY2024 Earnings of $3.82 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:GILD)
americanbankingnews.com - April 29 at 2:44 AM
Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call TranscriptGilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript
seekingalpha.com - April 29 at 12:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

DOW logo

DOW

NYSE:DOW
Dow Inc., through its subsidiaries, engages in the provision of various materials science solutions for packaging, infrastructure, mobility, and consumer applications in the United States, Canada, Europe, the Middle East, Africa, India, the Asia Pacific, and Latin America. The company operates through Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings segments. The Packaging & Specialty Plastics segment provides ethylene, and propylene and aromatics products; and polyethylene, polyolefin elastomers, ethylene vinyl acetate, and ethylene propylene diene monomer rubbers for mobility and transportation, consumer, wire and cable, and construction end-markets. The Industrial Intermediates & Infrastructure segment offers purified ethylene, ethylene and ethanol amines, propylene glycol and polyether polyols, aromatic isocyanates and coatings, adhesives, sealants, elastomers, and composites. This segment also provides caustic soda, and ethylene dichloride and vinyl chloride monomers; and cellulose ethers, redispersible latex powders, and acrylic emulsions. The Performance Materials and Coatings segment provides architectural paints and coatings, and industrial coatings that are used in maintenance and protective industries, wood, metal packaging, traffic markings, thermal paper, and leather; and silicon metal, siloxanes, and intermediates used as key materials in manufacturing differentiated downstream silicone products. It also engages in property and casualty insurance, as well as reinsurance business. Dow Inc. was incorporated in 2018 and is headquartered in Midland, Michigan.
Ethan Allen Interiors logo

Ethan Allen Interiors

NYSE:ETD
Ethan Allen Interiors Inc. operates as an interior design company, and manufacturer and retailer of home furnishings in the United States, Mexico, Honduras, and Canada. The company operates in two segments, Wholesale and Retail. Its products include case goods items, such as beds, dressers, armoires, tables, chairs, buffets, entertainment units, home office furniture, and wooden accents; upholstery comprising fabric-covered items, such as sleepers, recliners and other motion furniture, chairs, ottomans, custom pillows, sofas, loveseats, cut fabrics, and leather; and home accent items consisting of window treatments and drapery hardware, wall decors, florals, lighting, clocks, mattresses, bedspreads, throws, pillows, decorative accents, area rugs, wall coverings, and home and garden furnishings. The company markets and sells its products under the Ethan Allen brand through home furnishing retail networks and independent retailers, as well as through ethanallen.com website. It operates a network of design centers. Ethan Allen Interiors Inc. was founded in 1932 and is headquartered in Danbury, Connecticut.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.